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Abstract 
 
Background: Controlling risk factors such as dyslipidemia in patients with coronary artery disease, including 
candidates for coronary artery bypass grafting (CABG), is of great importance and has serious effects on CABG 
morbidity and mortality. The aim of this study was to evaluate lipid serum levels, comprising TG, LDL, and HDL, 
before CABG and their relation with in-hospital outcome.   
 
Methods: The clinical profiles of 3,593 patients in the hospital cardiac surgery databank who underwent isolated 
CABG between April 2006 and April 2008 were reviewed. Three components of lipid profile, including TG, LDL, 
and HDL serum levels, were checked at the time of hospitalization in all the patients. Lipid control was evaluated 
according to the published guidelines.  
 
Results: The mean LDL, HDL, and TG serum levels were 103.4±48.5, 40.9±16, and 168±87 mg/dl, respectively. 
Additionally, 487 (13.6%) patients had entire TG, LDL, and HDL serum levels within the acceptable range and in 
668 (18.6%) patients, all of these components were within the uncontrolled range. After adjustment for con-
founders, in-hospital mortality in patients with uncontrolled TG, LDL, and HDL was higher than patients with 
controlled TG, LDL, and HDL (p value=0.042, OR=1.399, 95% CI =1.012-1.934).  
 
Conclusion: The high prevalence of uncontrolled lipids in our patient population is alarming. Regular and fre-
quent pre- and post-operative visits to monitor and modify patient risk factors, including dyslipidemia, seem nec-
essary. An increase in statin dosage or adjunctive therapy with other lipid lowering agents may be helpful. At-
tempts to maintain all lipids within the controlled range may have beneficial effects on hospital outcome. 
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Introduction 
 
The control of the risk factors of coronary heart dis-
ease (CHD) as a secondary prevention, is still very 
unsatisfactory and inadequate.
1 Its role in CHD con-
trol, however, even in decreasing post-coronary artery 
bypass grafting (CABG) morbidity and mortality, is 
currently acceptable. Sufficient control of low density 
lipoprotein (LDL) serum level, less than 100 mg/dl, is 
one of the highly recommended secondary prevention 
plans in patients with CHD, especially in those  for 
whom CABG is scheduled.
2-4 Statin should be pre-
scribed for all patients before undergoing CABG with 
a view to achieve an LDL-C serum level of less than 
100 mg/dl in patients undergoing elective CABG and 
less  than  70  mg/dl  in  high-risk  patients.
5,6  Pre-
operative statin therapy in patients undergoing CABG 
not only improves the post-operative myocardial per-
fusion of  bypassed areas,
7 but also has several bene-
ficial effects on the patency of saphenous vein con-
duit grafts by improving the endothelial function and 
inhibiting  the  proliferation  of  smooth  muscle  cells 
that could decrease the speed of atherosclerosis pro-
gression in the vein graft conduits in CABG.
8,9 Statin 
has  also  beneficial  effects  on  decreasing  peri-
operative and long-term mortality and morbidity of 
redo revascularization in CABG patients.
5 Nonethe-
less, there are still reports of inadequate lipid control 
in large proportions of these patients.
10-12 The aim of 
 
 
 
 
*Correspondence: Maryam Mehrpooya, MD, Department of Cardi-
ology, Tehran Heart Center, Tehran University of Medical Sciences, 
Tehran,  Iran.  Tel:  +98-21-61192647,  Fax:  +98-21-66939537,  
e-mail: mehrpooya@razi.tums.ac.ir 
Received: June 10, 2010, Revised: October 10, 2010, Accepted: 
October 18, 2010 Lipid control before CABG 
 
WWW.ircmj.com Vol 13 February 2011  107 
this  study  was  to  evaluate  pre-CABG  lipid  control 
and its association with in-hospital outcome.   
 
 
Materials and Methods  
 
From April 2006 to April 2008, 3,593 patients who 
underwent CABG were enrolled. All medical records 
of  patients  were  derived  from  our  hospital  cardiac 
surgery databank.
13,14 The patients were referred by 
cardiologists of our center or other centers and clin-
ics. The  serum  lipid  levels were  checked  upon  the 
patients’ hospitalization. All definitions of the varia-
bles were according to our hospital cardiac surgery 
data  bank.
13,14  The  inclusion  criteria  were  coronary 
artery disease and candidacy for isolated CABG.  
LDL of 100 mg/dl or more, triglyceride (TG) of 
150  mg/dl  or  more,  and  high  density  lipoprotein 
(HDL) of 45 mg/dl or less in men and 55mg/dl or less 
in  women.  Statistical  analysis  was  performed  with 
SPSS-15  (SPSS  –I  ncm,  Chicago,  IL,  USA)  using 
the Chi-Square and  t tests and analysis of variance. 
The  univariate  analysis  of  the  continuous  variables 
was carried out using Student’s T-test, and the cate-
gorical  variables  were  compared  using  the  Chi-
Square or Fisher’s exact test. Multivariable logistic 
regression model for comparing mortality in the two 
groups of uncontrolled TG and LDL and HDL versus 
controlled TG and LDL and HDL in the presence of 
confounders was constructed. The association of un-
controlled lipid profile and mortality was expressed 
as odds ratio (OR) with 95 percent confidence inter-
val. Differences were considered statistically signifi-
cant when a p value was less than 0.05. 
 
 
Results 
 
Among CABG patients, 2,695 (75%) cases were men 
and  898  (25%)  were  women  with  a  mean  age  of 
58.8±9.9 years. The demographic and characteristics 
of the patients are listed in Table 1. The status of sur-
gery in these patients was as follows: 2817 (79.1%) 
elective,  741  (20.8%)  urgent  and  4  (0.1%)  were 
emergent  CABGs.  In  total,  2,554  (71.6%)  patients 
had three-vessel coronary artery disease, 761 (21.3%) 
two-vessel  disease,  and  252  (7.1%)  a  single-vessel 
disease.  Additionally,  273  (7.6%)  patients  had  left 
main disease. The mean values of serum lipid levels 
were  as  follows:   LDL  of  103.16±39.1,  HDL  of 
40.91±16.12, and TG of 168.8±87.09 mg/dl.  
In 487 (13.6%) patients, the entire TG, LDL, and 
HDL serum levels were within the acceptable range; 
and in 668 (18.6%) patients, none of these compo-
nents was controlled. In 1,032 (28.7%) patients LDL 
and HDL; in 389 (10.8%) patients LDL and TG; and 
in 474 (13.2%) patients HDL and TG serum levels 
were in the uncontrolled range (Table 1). Table 2 lists 
Table 1: Baseline patients' characteristics 
Characteristics  Men (N=2695)  
No (%) 
Women (N=898) 
No (%) 
Total 
No (%) 
Cigarette smoking
a  1309(48.6)  62(6.9)  1371(38.2) 
Hypertension   1233(45.9)  631(70.3)  1864(52) 
Diabetes  778(28.9)  325(36.2)  1103(30.7) 
Hypercholesterolemia  1766(65.7)  677(75.8)  2443(68.2) 
Uncontrolled LDL  
(100 mg/dl≤) 
1228(46.6)  447(51.6)  1675(46.6) 
Uncontrolled HDL  
(≤55 mg/dl in women ) 
(≤45 mg/dl in men) 
2347(87.1)  740(82.4)  3087(85.9) 
Mean angiographic EF  48.48%  51.48%  49.26% 
History of myocardial infarction  1232(45.7)  340(37.8)  1573(43.8) 
History of renal failure  52(1.9)  25(2.7)  77(2.1) 
History of  cerebrovascular ac-
cident 
91(3.3)  61(6.7)  153(4.2) 
History of peripheral vascular 
disease 
69(2.5)  31(3.4)  100(2.7) 
History of previous CABG  8(0.3)  0  8(0.2) 
aLDL, low density lipoprotein; HDL, High density lipoprotein; EF, ejection fraction; CABG, Coronary artery bypass 
grafting  
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the cumulative frequency of the categorized LDL se-
rum levels in the CABG patients. The total in-hospital 
mortality rate was 1.4 % (47 patients). The incidence 
of uncontrolled serum LDL, HDL, and TG in the pa-
tients who died was 48%, 87.7%, and 52.1%, respec-
tively;  compared  respectively  with  51.5%,  85.5%, 
and 50.8% of those who survived.  No significant dif-
ference was noticed in lipid profile levels between the 
dead and surviving cases (p value>0.05). However, 
in-hospital mortality in the patients with  controlled 
TG, LDL, and HDL was 0.6 % and in those with un-
controlled TG, LDL, and HDL was 2.4 %, which was 
significantly different (p value=0.019) (Table 3). Af-
ter  adjustment  for  confounding  variables  including 
age, body mass index (BMI), smoking, hypertension 
(HTN), diabetes mellitus (DM), angiographic ejection 
fraction (EF),  history of renal failure (RF), history of 
peripheral vascular disease (PVD), history of pervi-
ous CABG, left main disease (LM) and three vessel 
disease  (3VD)  (Table  4);  in  hospital  mortality  rate 
remained  higher  among  patients  with  uncontrolled 
TG, LDL, and HDL versus those with controlled TG, 
LDL, and HDL (Odds ratio=1.399, 95% CI =1.012-
1.934, p value=0.042). Regarding mortality between 
other groups, the difference was not significant (Ta-
ble  3).  Lipid  lowering  agents  were  prescribed  in 
3,126 (87.3%) patients post-operatively. These agents 
were  not  administered  in  453  (12.7%)  patients  be-
cause of intolerance or other contraindications. 
 
 
Discussion 
 
Although the mean LDL serum level in our study was 
near the acceptable range, it was  evident that LDL 
was not under control in about half of the study popu-
lation. Also, in a relatively large proportion of this 
group of patients, HDL was less than the optimal lev-
el  (<55  mg  /dl  in  women  and  <45  mg/dl  in  men). 
LDL, HDL, and TG control was achieved in a small 
proportion of our patients. This fact may in part be 
due to the finding that about 21% of the patients had 
undergone urgent or emergent CABG and thus there 
may not have been enough time to reach the goal of 
Table 2: Commulative frequency of categorized LDL serum levels in CABG patients 
LDL levels (mg/dl)  Frequency  Percentage
a  Cumulative percentage 
<70  685  19.6  19.6 
70-99  1115  31.9  51.5 
100-129  877  25.1  76.5 
130-159  542  15.5  92 
160-189  200  5.7  97.7 
≥190  79  2.3  100 
Total  3498
a  100   
aValid percentage was used because about 2.5% was missing. LDL, low density lipoprotein 
 
Table 3: Comparison between combined dyslipidemia and in-hospital mortality 
Groups
a  Total cases  In hospital mortality (rate %) 
Controlled all lipids  487  3 (0.61) 
Uncontrolled one lipid  543  8 (1.47) 
Uncontrolled HDL and LDL  1032  9 (0.87) 
Uncontrolled TG and LDL  389  5 (1.3) 
Uncontrolled TG and HDL  474  6  (1.26) 
Uncontrolled HDL, LDL and TG  668  16(2.40) 
All cases  3593  47 (1.31) 
aThe Comparison between “Controlled all Lipids” and “All Cases”: P>0.05(NS), The Comparison between “Con-
trolled all Lipids” and “Uncontrolled HDL & LDL & TG”: P=0.019, The Comparison between “Uncontrolled HDL & 
LDL” and “Uncontrolled TG & LDL”: P>0.05(NS), The Comparison between “Uncontrolled HDL & LDL” and “Un-
controlled TG & HDL”: P>0.05(NS), The Comparison between “Uncontrolled TG & LDL” and “Uncontrolled TG & 
HDL”: P>0.05(NS), The Comparison between “Uncontrolled HDL & LDL” and “All Cases”: P>0.05(NS), The Com-
parison between “Uncontrolled TG & LDL” and “All Cases”: P>0.05(NS), The Comparison between “Uncontrolled 
TG & HDL” and “All Cases”: P>0.05(NS), NS, non-significant; P-value>0.05, LDL, low density lipoprotein; HDL, 
High density lipoprotein; TG, triglyceride 
 Lipid control before CABG 
 
WWW.ircmj.com Vol 13 February 2011  109 
control. This finding is in agreement with that of the 
Paraskevas and colleagues review study,
5 which stat-
ed that a large percentage of cardiothoracic surgical 
patients were suboptimally treated with statin. Anoth-
er study reported that the prevalence of risk factors in 
CABG patients was very high; and despite a high lev-
el of medical treatment, risk factor management was 
very poor.
15 Another reason for this high percentage 
of uncontrolled lipid levels may be due to the insuffi-
cient effect of statin in some patients. As was stated 
in other studies,
16,17 increase in statin dosage or add-
ing other lipid lowering agents as combination thera-
py such as ezetimibe or lipid binding resins could fa-
cilitate attaining favorable serum LDL levels in pa-
tients.   
There is some debate about the role of lipid lower-
ing therapy in the outcome of cardiovascular surgical 
procedures. In our study, the mean of TG, LDL, and 
HDL serum levels was not significantly different be-
tween the dead and surviving patients. Nevertheless, a 
statistically  significant  difference  was  observed  in 
terms of in-hospital mortality in the patients with con-
trolled TG, LDL, and HDL as opposed to the patients 
who had uncontrolled TG, LDL, and HDL. This is the 
original and  main finding  of the  present study  and 
chimes in with a recent systematic review showing 
that statin can be protective in patients  undergoing 
cardiac  and  non-cardiac  surgeries.
18  Another  meta 
analysis of 13 controlled studies (including 3 random-
ized controlled trials) demonstrated that pre-operative 
statin therapy reduced post-operative mortality in pa-
tients with cardiac surgery.
19 On the other hand, Pow-
ell and colleagues stated that lipid lowering therapy 
before CABG was not associated with decreased in-
hospital mortality or morbidity, including cerebrovas-
cular  events,  reoperation  for  bleeding,  and  post-
operative atrial fibrillation.
20 Another study with find-
ings  that  disagree  with  those  in  the  present  study 
looked  into  1,308  matched  patients  after  isolated 
CABG and concluded that pre-operative statin use did 
not  reduce  peri-operative  mortality  or  morbid 
events.
21 It seems that more studies are required to 
further elucidate this controversial issues. 
Discontinuation of pre-operative statin therapy fol-
lowing CABG is another important issue that could lead 
to adverse effects and mortality in comparison with pa-
tients whose statin treatment is continued following the 
procedure.
5,22  Lipid  lowering  agents  were  continued 
post-operatively in 87.3% of our study population. 
There is still room for improvement in lipid con-
trol  issue  in  CABG  patients.  Regular  and  frequent 
pre-operative  and  post-operative  visits  are  recom-
Table 4: Comparison of variables among survivors and dead patients 
Variable   Surviving 
(N=3546) 
Dead  
(N=47) 
P-value 
Age   58.71±9.90
  63.72±9.10  0.001 
Male gender  2663 (75.1%)  32 (68.1%)  0.270 
BMI (Kg/m
2)   27.42±4.06  25.73±4.48  0.005 
Smoking 
a   1358 (39.4%)  12 (25.5%)  0.054 
DM
a  1198 (33.9%)  23 (48.9%)  0.031 
HTN
a  1833 (51.8%)  32 (68.1%)  0.026 
(+) Family history
a  1598 (45.6%)  20 (44.4%)  0.875 
Angina   3272 (92.3%)  42 (89.4%)  0.409 
Angiographic EF  49.45±9.45  46.05±11.16  0.019 
Hx of CVA  150(4.2%)  3 (6.4%)  0.452 
Hx of PVD  95 (2.7%)  5 (10.6%)  0.009 
Hx of CABG  6 (0.16%)  2 (4.25%)  0.004 
Hx of MI   1552 (43.8%)  21 (44.7%)  0.903 
LM disease   265 (7.47%)  8 (17.02%)  0.054 
3VD
a   2515 (71.4%)  39 (86.7%)  0.024 
Hx of renal failure  70 (1.97%)  5 (10.6%)  0.003 
Triglyceride  173.3±32.8  170.5±27.7  0.842 
LDL  98.16±35.2  101±28.1  0.658 
HDL  42.6±9.1  40.12±6.5  0.958 
aThere may be small percentage (less than 2%) missing rate in some variables. Data are presented as Mean±SD 
or No (%), CVA=cerebrovascular accident, PVD=peripheral vascular disease, Hx=history of, BMI=body mass in-
dex, LDL=low density lipoprotein, HDL=high density lipoprotein, MI=myocardial infarction 
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mended in order to lower serum LDL to suggested 
levels of less than 100 mg/dl and less than 70 mg/dl 
in high-risk patients by modern management of CHD 
patients.  Maintaining  TG,  HDL,  and  LDL  levels 
within  the  optimal  range  seems  to  have  a  positive 
bearing on CABG outcome. Statin therapy or even 
combination  therapy  based  on  patient  conditions  is 
suggested for  achieving  optimal lipid  serum  levels. 
Further studies are required and suggested for evalu-
ating  the  optimal  timing  of  elective  surgery  after 
commencing statin treatment to take full advantage of 
these agents.  
 
 
Acknowledgment 
 
We extend our gratitude to Doctor Mahmood Sheikh 
Fathollahi for helping us in statistical analysis. 
 
Conflict of interest: None declared.  
 
 
References 
 
 
 
1  Ladeia  AM,  Guimarães  AC.  As-
sessment of Risk Factors in  Coro-
nary  Patients  Being  Followed  by 
Cardiologists:  Control  of  Risk  Fac-
tors in Coronary Patients. Prev Car-
diol. 2003;6:122-7. [15319581] [doi: 
10.1111/j.1520-037X.2003.01967.x] 
2  ALLHAT  Officers  and  Coordinators 
for  the  ALLHAT  Collaborative  Re-
search Group. The Antihypertensive 
and  Lipid-Lowering  Treatment  to 
Prevent  Heart  Attack  Trial.  Major 
outcomes  in  moderately  hypercho-
lesterolemic,  hypertensive  patients 
randomized to pravastatin vs usual 
care:  The  Antihypertensive  and  Li-
pid-Lowering  Treatment  to  Prevent 
Heart  Attack  Trial  (ALLHAT-LLT). 
JAMA.  2002;288:2998-3007.  [1247 
9764] 
3  Colhoun  HM,  Betteridge  DJ,  Dur-
rington  PN,  Hitman  GA,  Neil  HA, 
Livingstone  SJ,  Thomason  MJ, 
Mackness  MI,  Charlton-Menys  V, 
Fuller  JH.  CARDS  investigators. 
Primary  prevention  of  cardiovascu-
lar disease with atorvastatin in type 
2  diabetes  in  the  Collaborative 
Atorvastatin  Diabetes  Study 
(CARDS):  multicentre  randomised 
placebo-controlled  trial.  Lancet. 
2004;364:  685-96.  [15325833] 
[doi:10.1016/S0  140-
6736(04)16895-5] 
4  Collins  R,  Armitage  J,  Parish  S, 
Sleigh P, Peto R; Heart Protection 
Study  Collaborative  Group.  MRC/ 
BHF Heart Protection Study of cho-
lesterol-lowering with simvastatin in 
5963  people  with  diabetes:  a  ran-
domised  placebo-controlled  trial. 
Lancet  2003;361:2005-16.  [1281 
4710]  [doi:10.1016/S0140-6736(03) 
13636-7] 
5  Paraskevas  KI.  Applications  of 
statins  in  cardiothoracic  surgery: 
more than just lipid-lowering. Eur J 
Cardiothorac Surg. 2008;33:377-90. 
[18248999] 
[doi:10.1016/j.ejcts.2007.12.010]  
6  Lazar  HL.  Should  all  patients  
receive  statins  before  cardiac  
surgery? Are more data necessary? 
J  Thorac  Cardiovasc  Surg.  2006; 
131:520-2.  [16515899]  [doi:10.10 
16/j.jtcvs.2005.10.023] 
7  Dotani  MI,  Morise  AP,  Haque  R, 
Jain AC, Gupta N, Gibson CM. As-
sociation  between  short-term 
simvastatin therapy before coronary 
artery  bypass  grafting  and  postop-
erative myocardial blood flow as as-
sessed by positron emission tomog-
raphy. Am J Cardiol. 2003;91:1107-
9.  [12714156]  [doi:10.1016/S0002-
9149(03)00158-9] 
8  The effect of aggressive lowering of 
low-density  lipoprotein  cholesterol 
levels  and  low-dose  anticoagulation 
on obstructive changes in saphenous-
vein  coronary-artery  bypass  grafts. 
The  Post  Coronary  Artery  Bypass 
Graft  Trial  Investigators.  N  Engl  J 
Med.  1997;336:153-62.  [8992351] 
[doi: 
10.1056/NEJM199701163360301] 
9  Yang  Z,  Kozai  T,  van  der  Loo  B, 
Viswambharan H, Lachat M, Turina 
MI,  Malinski  T,  Lüscher  TF.  HMG-
CoA  reductase  inhibition  improves 
endothelial cell function and inhibits 
smooth  muscle  cell  proliferation  in 
human saphenous veins. J Am Coll 
Cardiol.  2000;36:1691-7.  [110796 
78]  [doi:10.1016/S0735-1097(00) 
00924-4] 
10  Iqbal MP, Sharif HM, Mehboobali N. 
Variability in lipid profile before and 
after coronary artery bypass grafting 
(CABG).  J  Pak  Med  Assoc.  2005; 
55:95-8. [15852742]  
11  Iwata A, Miura S, Shirai K, Kawamu-
ra A, Tomita S, Matsuo Y, Zhang B, 
Nishikawa H, Kumagai K, Matsuo K, 
Saku K. Lower level of low-density 
lipoprotein cholesterol by statin pre-
vents  progression  of  coronary 
restenosis after successful stenting 
in acute myocardial infarction. Intern 
Med.  2006;45:885-90.  [16  946569] 
[doi:10.2169/internalmedicine. 
45.1757] 
12  Ooi M, Cooper A, Lloyd G, Jackson 
G. A study of lipid profile before and 
after  coronary  artery  bypass  graft-
ing. Br J Clin Pract 1996;50:433-5. 
[9039713] 
13  Karimi AA, Ahmadi SH, Davoodi S, 
Marzban M, Movahedi N, Abbasi K, 
Omran  AS,  Shirzad  M,  Sadeghian 
S,  Abbasi  SH,  Lotfi-Tokaldany  M, 
Soleymanzadeh M, Fehri A, Fathol-
lahi  MS.  First  database  report  on 
cardiothoracic  surgery  in  Tehran 
Heart Center. Iran J Public. Health 
2008;37:1-8. 
14  Karimi  A,  Ahmadi  H,  Davoodi  S, 
Movahedi N, Marzban M, Abbasi K, 
Omran AS, Sadeghian S, Yazdani-
fard P, Abbasi SH, Fallah N. Factors 
affecting  postoperative  morbidity 
and mortality in isolated coronary ar-
tery bypass graft surgery. Surg To-
day.  2008;38:890-8.  [18820863] 
[doi: 10.1007/s00595-007-3733-z] 
15  Baskett  RJ,  Buth  KJ,  Collicott  C, 
Ross DB, Hirsch GM. Preoperative 
cardiovascular risk factor control in 
elective coronary artery bypass graft 
patients:  A  failure  of  present  man-
agement.  Can  J  Cardiol.  2002;18: 
397-402. [11992133] 
16  Hou  R,  Goldberg  AC.  Lowering 
Low-Density  Lipoprotein  Cholester-
ol: Statins, Ezetimibe, Bile Acid Se-
questrants,  and  Combinations: 
Comparative  Efficacy  and  Safety. 
Endocrinol  Metab  Clin  North  Am. 
2009; 38:79-97. [19217513] [doi:10. 
1016/j.ecl.2008.11.007] 
17  Davidson  MH.    Reducing  Residual 
Risk for Patients on Statin Therapy: 
The  Potential  Role  of  Combination 
Therapy.  Am  J  Cardiol.  2005;96: 
3K-13K.  [16291008] 
[doi:10.1016/j.amjcard.2005.08.002] 
18  Howard-Alpe G, Foex P, Biccard B. 
Cardiovascular  protection  by  anti-
inflammatory  statin  therapy.  Best 
Pract Res Clin Anaesthesiol. 2008; Lipid control before CABG 
 
WWW.ircmj.com Vol 13 February 2011  111 
22:111-33.  [18494392]  [doi:10.10 
16/j.bpa.2007.08.001] 
19  Takagi  H,  Kawai  N,  Umemoto  T. 
Preoperative statin therapy reduces 
postoperative  all-cause  mortality  in 
cardiac surgery: A meta-analysis of 
controlled studies. J Thorac Cardio-
vasc Surg. 2009;137:e52-3. [191548 
87] [doi:10.1016/j.jtcvs.2008.02.045] 
20  Powell  BD,  Bybee  KA,  Valeti  U, 
Thomas  RJ,  Kopecky  SL,  Mullany 
CJ,  Wright  RS.  Influence  of  Pre-
operative  Lipid-Lowering  Therapy 
on  Postoperative  Outcome  in  Pa-
tients  undergoing  Coronary  Artery 
Bypass  Grafting.  Am  J  Cardiol 
2007;99:785-9.  [17350365] 
[doi:10.1016/j.amjcard.2006.10.036] 
21  Subramaniam K, Koch CG, Bashour 
A, O'Connor M, Xu M, Gillinov AM, 
Starr NJ. Preoperative statin intake 
and  morbid  events  after  isolated 
coronary  artery  bypass  grafting.  J 
Clin  Anesth.  2008;20:4-11. 
[18346602] 
[doi:10.1016/j.jclinane.2007.09.003] 
22  Collard CD, Body SC, Shernan SK, 
Wang S, Mangano DT. Multicenter 
Study  of  Perioperative  Ischemia 
(MCSPI)  Research  Group,  Inc;  Is-
chemia  Research  and  Education 
Foundation  (IREF)  Investigators. 
Preoperative statin therapy is asso-
ciated with reduced cardiac mortality 
after  coronary  artery  bypass  graft 
surgery. J Thorac Cardiovasc Surg. 
2006;132:392-400. [16872968] [doi: 
10.1016/j.jtcvs.2006.04.009] 
 